ArticleInternational journal of molecular sciences2018
The Effect of Human Mesenchymal Stem Cells Derived from Wharton's Jelly in Spinal Cord Injury Treatment Is Dose-Dependent and Can Be Facilitated by Repeated Application.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The optimal transplantation strategy of umbilical cord mesenchymal stem cells in spinal cord injury: a systematic review and network meta-analysis based on animal studies.Stem cell research & therapy · 2022Pooled it
- Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels.Stem cells translational medicine · 2019Trial
- Intrathecal injection of 3D-mesenchymal stem cells attenuates disseminated neuroinflammation and improves cognitive function in controlled cortical impact rats.Frontiers in neuroscience · 2026Article
- Clinical Insights into Mesenchymal Stem Cell Applications for Spinal Cord Injury.International journal of molecular sciences · 2025Review
- Article
- A novel antibacterial hydrogel containing aminophylline as a versatile platform for neural differentiation of hWJMSCs through the CREB pathway.Scientific reports · 2025Article
- Systemic stem cell treatment rescues injured motoneurons by reducing L-selectin expression on leukocytes.Stem cell research & therapy · 2025Article
- Progression of mesenchymal stem cell regulation on imbalanced microenvironment after spinal cord injury.Stem cell research & therapy · 2024Review
- Application and challenges of stem cells in cardiovascular aging.Regenerative therapy · 2024Review
- Safe Reversal of Motor and Sensory Deficits by Repeated High Doses of Mesenchymal Stem Cells in a Patient with Chronic Complete Spinal Cord Injury.The American journal of case reports · 2023Article
- The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment of Spinal Cord Injury.Antioxidants (Basel, Switzerland) · 2023Article
- Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges.Frontiers in immunology · 2023Review
- Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for Spinal Cord Injury.Cells · 2022Review
- Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury.Neural regeneration research · 2022Article
- Article
- Clinical Trials Using Mesenchymal Stem Cells for Spinal Cord Injury: Challenges in Generating Evidence.Cells · 2022Review
- Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.Frontiers in molecular neuroscience · 2022Review
- Mesenchymal Stromal Cell Therapy in Spinal Cord Injury: Mechanisms and Prospects.Frontiers in cellular neuroscience · 2022Review
- Review
- Cell therapy and delivery strategies for spinal cord injury.Histology and histopathology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human mesenchymal stem cells derived from Wharton's jelly (WJ-MSCs) were used for the treatment of the ischemic-compression model of spinal cord injury in rats. To assess the effectivity of the treatment, different dosages (0.5 or 1.5 million cells) and repeated applications were compared. Cells or saline were applied intrathecally by lumbar puncture for one week only, or in three consecutive weeks after injury. Rats were assessed for locomotor skills (BBB, rotarod, flat beam) for 9 weeks. Spinal cord tissue was morphometrically analyzed for axonal sprouting, sparing of gray and white matter and astrogliosis. Endogenous gene expression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.